Evaluating the Role of Treatment Accessibility in HIV-TB Co-Infection: A Comparative Approach Using Fractional-Order Modeling - Top-Institutions - MDSpire

Evaluating the Role of Treatment Accessibility in HIV-TB Co-Infection: A Comparative Approach Using Fractional-Order Modeling

  • By

  • Agbata Benedict Celestine

  • Mehmet Gümüş

  • A. K. Awasthi

  • Homan Emadifar

  • Aseel Smerat

  • Bolarinwa Bolaji

  • February 14, 2026

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Infectious Diseases
    • Epidemiology
    • Mathematical Modeling

  • #2

    University of Cape Town
    University of Cape Town

    Cape Town, Western Cape

    Key Differentiators

    • Infectious Diseases
    • Public Health
    • HIV/TB Clinical Research

  • #3

    Centers for Disease Control and Prevention (CDC)
    Centers for Disease Control and Prevention (CDC)

    Atlanta, GA

    Key Differentiators

    • Infectious Disease Control
    • Epidemiology
    • Global Health

  • #4

    Imperial College London
    Imperial College London

    London, England

    Key Differentiators

    • Infectious Diseases
    • Mathematical Modeling
    • Global Health

  • #5

    The University of California, San Francisco (UCSF)
    The University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Infectious Diseases
    • HIV Research
    • Clinical Trials

Original Source(s)

Evaluating the Role of Treatment Accessibility in HIV-TB Co-Infection: A Comparative Approach Using Fractional-Order Modeling

  • by Agbata Benedict Celestine, Mehmet Gümüş, A. K. Awasthi, Homan Emadifar, Aseel Smerat, Bolarinwa Bolaji

  • February 14, 2026

Related Content

Antibiotic Falls Short in Disc-Related Back Pain

A randomized trial found no greater pain reduction vs placebo, but questions remain about patients with type 1 Modic changes.

7 Days Noninferior in Bacteremia

BALANCE compared 7 vs 14 days of treatment among hospitalized patients with bloodstream infections.

FDA Approves Cefepime-Zidebactam Injection

Phase 3 ENHANCE-1 results showed higher composite clinical cure and microbiologic response rates with cefepime-zidebactam vs meropenem in hospitalized adults with complicated urinary tract infection or acute pyelonephritis.